ADMA Biologics(US:ADMA)2026-02-25 22:16Financial Performance - For the fiscal year ended December 31, 2024, ADMA achieved a net income of $197.7 million, marking the first time in its history that it reported net income on a GAAP basis, alongside positive cash flow from operations of $118.7 million [354]. - Total revenues for the year ended December 31, 2025, were $510.2 million, an increase of $83.7 million, or 20%, compared to $426.5 million in 2024 [374]. - Net income for 2025 was $146.9 million, a decrease of $50.7 million compared to $197.7 million in 2024 [373]. - Adjusted EBITDA for 2025 was $231.0 million, an increase of $66.4 million from $164.6 million in 2024 [373]. - Gross profit for 2025 was $292.8 million, representing a gross margin of 57.4%, up from 51.5% in 2024 [377]. - Gross profit for the year ended December 31, 2024, was $219.6 million, up from $88.9 million in 2023, resulting in a gross margin of 51.5% compared to 34.4% in the prior year [392]. - The effective tax rate for 2025 was 19.6%, with an income tax expense of $35.7 million [385]. Sales and Product Development - ASCENIV's prescriber and patient base expanded significantly in 2024, driving record utilization, with expectations for continued rapid growth through 2026 [361]. - ASCENIV sales increased by $122.9 million, or 51%, reaching $362.5 million in 2025, while BIVIGAM sales decreased by $20.3 million, or 14% [374]. - In June 2025, ADMA filed a supplemental Biologics License Application (sBLA) for ASCENIV to expand its label to include pediatric patients aged two years and older, with potential FDA approval anticipated in H1 2026 [362]. - The company anticipates submitting a pre-Investigational New Drug (IND) package for its S. pneumoniae hyperimmune globulin program, SG-001, in fiscal year 2026, potentially leading to a registrational clinical trial [350]. Operational Expansion - In July 2025, ADMA completed the acquisition of real estate in Boca Raton, FL for $12.6 million to expand production operations and improve storage capabilities [357]. - ADMA entered into an agreement for the divestiture of three plasma collection centers for a total of $12.0 million, with two centers already sold and the third expected to close in Q1 2026, enhancing capital efficiency and plasma supply [358]. - The company operates eight FDA-licensed plasma collection facilities, each capable of collecting approximately 30,000 to 50,000 liters of source plasma annually, contributing to its supply chain [352]. - ADMA's Boca Facility has a peak annual processing capability of up to 600,000 liters, supporting the production of immune globulin products [351]. Expenses and Financial Management - Research and development expenses rose to $4.8 million in 2025, compared to $1.8 million in 2024, driven by investments in SG-001 [378]. - Selling, general and administrative expenses increased by $17.5 million, or approximately 24%, totaling $91.6 million in 2025 [381]. - Interest expense decreased to $7.1 million in 2025 from $13.9 million in 2024, due to lower debt balances and interest rates [382]. - Research and development expenses decreased to $1.8 million in 2024 from $3.3 million in 2023, primarily due to the absence of BIVIGAM post-marketing commitments [393]. - Selling, general and administrative expenses rose to $74.1 million in 2024, an increase of $15.1 million from 2023, with SG&A as a percentage of net revenues decreasing from 22.9% to 17.4% [396]. Debt and Financing - The company entered into a senior secured credit facility with Ares Capital Corporation totaling $135.0 million, consisting of a $62.5 million term loan and a $72.5 million revolving credit facility, both fully drawn on December 18, 2023 [413]. - The company recorded a total loss on extinguishment of debt amounting to $26.2 million during the year ended December 31, 2023, due to the termination of the previous Hayfin Credit Facility [413]. - As of December 31, 2024, the outstanding balance on the Ares revolving credit facility was $42.5 million, with an additional $30.0 million available [415]. - The company entered into a new Credit Agreement with JPMorgan Chase Bank on August 5, 2025, providing for $300 million in senior secured credit facilities [420]. - As of December 31, 2025, the interest rate on the JPM Term Loan Facility was approximately 6.42%, with no borrowings outstanding under the JPM Revolving Facility [422]. Cash Flow and Investments - Working capital increased to $397.0 million at December 31, 2025, compared to $275.9 million at December 31, 2024, with positive cash flow from operations of $50.4 million in 2025 [409]. - Net cash provided by operating activities for the year ended December 31, 2025 was $50.4 million, a decrease from $118.7 million in 2024, primarily due to inventory investments [428]. - Cash used in investing activities increased to $21.9 million in 2025, driven by capital expenditures related to the Yield Enhancement project and the acquisition of real estate [430]. - Net cash used in financing activities for the year ended December 31, 2025 was $44.0 million, which included debt repayments and treasury stock acquisitions [432]. Economic and Market Conditions - Inflation has impacted various aspects of the business, leading to increased costs in raw materials, labor, and transportation, with expectations for some relief in 2026 [433]. - The company does not believe inflation had a material effect on its business or financial condition as of December 31, 2025 [435]. - Scheduled price increases in third-party inventory purchase agreements are tied to consumer price indices, potentially leading to higher costs in 2026 and beyond [433]. - Disruptions in global supply chains have resulted in longer lead times and delays in procuring certain raw materials [433]. - The company anticipates that geopolitical conditions may significantly impact future operational results [433]. - Price increases for consumable supplies and services have been observed, affecting overall operational costs [433]. - The company may face challenges in raising product prices to keep pace with inflation in a higher inflationary environment [433]. - Inflation has generally increased research and development, labor, clinical trials, and manufacturing costs [435].